Skip to main content

Glucocorticoid and Breviscapine Combination Therapy Versus Glucocorticoid Alone on Sudden Sensorineural Hearing Loss in Patients with Different Audiometric Curves

Abstract

Introduction

We aimed to retrospectively analyze the therapeutic outcomes of using glucocorticoid combined with a vasodilator, breviscapine, versus glucocorticoid alone in patients with sudden sensorineural hearing loss (SSNHL) and to explore the impact on different audiometric curves.

Methods

Data from 154 patients were collected between January 2017 and December 2018. Patients received treatments of either glucocorticoid combined with breviscapine (GC + Bre) or glucocorticoid alone (GC). These two groups were stratified into low frequencies SSNHL (LF-SSNHL), high frequencies SSNHL (HF-SSNHL), all frequencies SSNHL (AF-SSNHL), and total deafness SSNHL (TD-SSNHL) subgroups according to their corresponding audiograms. The hearing level was evaluated by pure tone audiometry, and hearing recovery was calculated by comparing the pure tone average (PTA) at pretreatment and 4 weeks after therapy.

Results

Hearing recovery was significantly greater for GC + Bre than GC-only treatment in the AF-SSNHL and TD-SSNHL subgroups (P < 0.05) and to a lesser extent in the LF-SSNHL and HF-SSNHL subgroups (P > 0.05). Logistic regression analysis also showed a favorable outcome for SSNHL in the GC + Bre group (odds ratio 2.848, P < 0.05).

Conclusion

Treating SSNHL using glucocorticoid combined with breviscapine could be more beneficial than using glucocorticoid alone, especially for patients with AF-SSNHL and TD-SSNHL.

Trial Registration Number

ChiCTR18000170072

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Chandrasekhar SS, Tsai Do BS, et al. Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg. 2019;161(1_suppl):S1–S45.

    Article  Google Scholar 

  2. 2.

    Byl FM Jr. Sudden hearing loss: eight years' experience and suggested prognostic table. Laryngoscope. 1984;94(5 Pt 1):647–61.

    Google Scholar 

  3. 3.

    Hughes GB, Freedman MA, Haberkamp TJ, Guay ME. Sudden sensorineural hearing loss. Otolaryngol Clin N Am. 1996;29(3):393–405.

    CAS  Article  Google Scholar 

  4. 4.

    Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery. The Otolaryngology Head and Neck Surgery Branch of Chinese Medical Association. Guideline of diagnosis and treatment of sudden deafness (2015). Chin J Otorhinolaryngol Head Neck Surg. 2015;50(6):443–7.

    Google Scholar 

  5. 5.

    Chau JK, Lin JR, Atashband S, Irvine RA, Westerberg BD. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope. 2010;120(5):1011–21.

    Google Scholar 

  6. 6.

    Park KH, Lee CK, Lee JD, Park MK, Lee BD. Combination therapy with systemic steroids, an antiviral agent, anticoagulants, and stellate ganglion block for treatment of sudden sensorineural hearing loss. Korean J Audiol. 2012;16(2):71–4.

    CAS  Article  Google Scholar 

  7. 7.

    Bravenboer-de-Sousa M, Cazemier S, Stegeman I, Thomeer H. Use of vasodilators in idiopathic sudden sensorineural hearing loss: a systematic review. J Int Adv Otol. 2017;13(3):399–403.

    Article  Google Scholar 

  8. 8.

    Okada M, Hato N, Nishio SY, et al. The effect of initial treatment on hearing prognosis in idiopathic sudden sensorineural hearing loss: a nationwide survey in Japan. Acta Otolaryngol. 2017;137(sup565):S30–S3333.

    CAS  Article  Google Scholar 

  9. 9.

    Shim HS, Kim JS, Kim MG. Comparative analysis of the combined therapeutic effects of lipoprostaglandin E(1) on sudden idiopathic sensorineural hearing loss. J Audiol Otol. 2017;21(1):33–8.

    Article  Google Scholar 

  10. 10.

    Agarwal L, Pothier DD. Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2009;4:CD003422.

    Google Scholar 

  11. 11.

    Kanzaki J, Inoue Y, Ogawa K, et al. Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss. Auris Nasus Larynx. 2003;30(2):123–7.

    Article  Google Scholar 

  12. 12.

    Lee HY, Kim JC, Choi MS, Chang DS, Kim AY, Cho CS. Therapeutic effect of combined steroid-lipoprostaglandin E1 for sudden hearing loss: a propensity score-matched analysis. Am J Otolaryngol. 2015;36(1):52–6.

    Article  Google Scholar 

  13. 13.

    Zhang RW, Zhang YL, Wang JS, Lin YY, Shang B (1988) Isolation and identification of flavonoids from shortscape fleabane (Erigeron breviscapus). Chin Trad Herb Drug. 1988;19(5):199–201.

    Google Scholar 

  14. 14.

    Li XL, Li YQ, Yan WM, et al. A study of the cardioprotective effect of breviscapine during hypoxia of cardiomyocytes. Planta Med. 2004;70(11):1039–44.

    CAS  Article  Google Scholar 

  15. 15.

    Jia JH, Chen KP, Chen SX, Liu KZ, Fan TL, Chen YC. Breviscapine, a traditional Chinese medicine, alleviates myocardial ischaemia reperfusion injury in diabetic rats. Acta Cardiol. 2008;63(6):757–62.

    Article  Google Scholar 

  16. 16.

    Gao J, Chen G, He H, et al. Therapeutic effects of breviscapine in cardiovascular diseases: a review. Front Pharmacol. 2017;8:289.

    Article  Google Scholar 

  17. 17.

    Wei Y. Dengzhanxixin injection using character analysis in clinical based on real world HIS database. China J Chin Mater Med. 2012;37(18):2718–22.

    Google Scholar 

  18. 18.

    Liu X, Yao L, Sun D, et al. Effect of breviscapine injection on clinical parameters in diabetic nephropathy: a meta-analysis of randomized controlled trials. Exp Ther Med. 2016;12(3):1383–97.

    CAS  Article  Google Scholar 

  19. 19.

    Siegel LG. The treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Clin N Am. 1975;8(2):467–73.

    CAS  Article  Google Scholar 

  20. 20.

    Koc A, Sanisoglu O. Sudden sensorineural hearing loss: literature survey on recent studies. J Otolaryngol. 2003;32(5):308–13.

    Article  Google Scholar 

  21. 21.

    Lawrence R, Thevasagayam R. Controversies in the management of sudden sensorineural hearing loss: an evidence-based review. Clin Otolaryngol. 2015;40(3):176–82.

    CAS  Article  Google Scholar 

  22. 22.

    Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol. 1980;106(12):772–6.

    CAS  Article  Google Scholar 

  23. 23.

    Lou JZ, Rui B. Effect of breviscapine combined with octreotide on the inflammatory reaction and vasoactive substances in patients with severe acute pancreatitis. J Hainan Med Univ. 2017:47–50.

  24. 24.

    Guo C, Zhu Y, Weng Y, et al. Therapeutic time window and underlying therapeutic mechanism of breviscapine injection against cerebral ischemia/reperfusion injury in rats. J Ethnopharmacol. 2014;151(1):660–6.

    CAS  Article  Google Scholar 

  25. 25.

    Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res. 1983;53(5):557–73.

    CAS  Article  Google Scholar 

  26. 26.

    Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature. 1983;306(5939):174–6.

    CAS  Article  Google Scholar 

  27. 27.

    Hua ZG, Xiao W, Li W, Xie Z. Effects of breviscapine on isolated thoracic aorta rings of rats. Acad J Guangdong Coll Pharm. 1997:680–683.

  28. 28.

    Ohinata Y, Makimoto K, Kawakami M, Haginomori S, Araki M, Takahashi H. Blood viscosity and plasma viscosity in patients with sudden deafness. Acta Otolaryngol. 1994;114(6):601–7.

    CAS  Article  Google Scholar 

  29. 29.

    Lin L, Hua L, Cai HY, Yang WM. Effects of scutellarin on vascular endothelial growth factor and protein kinase Cε expression in human umbilical vein endothelial cells after ischemia-reperfusion injury. J Clin Rehabilit Tissue Eng Res. 2011:3723–3727.

  30. 30.

    Berjis N, Moeinimehr M, Hashemi SM, Hashemi SM, Bakhtiari EK, Nasiri S. Endothelial dysfunction in patients with sudden sensorineural hearing loss. Adv Biomed Res. 2016;5:5.

    Article  Google Scholar 

  31. 31.

    Chappey O, Wautier MP, Boval B, Wautier JL. Endothelial cells in culture: an experimental model for the study of vascular dysfunctions. Cell Biol Toxicol. 1996;12(4–6):199–205.

    CAS  Article  Google Scholar 

  32. 32.

    Zhang H, Wang XY, Liu Y, et al. Effects of dengzhan xixin injection on inflammatory cytokine production in rat cardiac microvascular cells induced by tumor necrosis factor. Chin Pharma J. 2009;44(23):1791–5.

    CAS  Google Scholar 

  33. 33.

    Song Y, Zhang HM, Jian-Jian MA, Chang-Ling LI. Effects of scutellarein on thrombosis and hemorheology in rats. Chin J New Drugs. 2011;20(15):1446–9.

    CAS  Google Scholar 

Download references

Acknowledgements

Acknowledgements

We thank the participants of the study.

Funding

This research was funded by the National Natural Science Foundation of China (No. 81771015) and the Shanghai Municipal Education Commission/Gaofeng Clinical Medicine Grant Support (No. 20152526) to Yanmei Feng.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contributions

Zhong Zheng wrote the manuscript. Ying Shen, Liang Xia analysed data. Hongmin Wu, Huiqun Zhou, Xulan Tang, Lili Meng, Hui Wang, Yaqin Wu collected data. Haibo Shi, Shankai Yin gave suggestions on the data acquisition and analysis. Yanmei Feng and Zhengnong Chen designed and supervised the research. All authors reviewed the manuscript.

Disclosures

Zhong Zheng, Ying Shen, Liang Xia, Hongmin Wu, Huiqun Zhou, Xulan Tang, Lili Meng, Hui Wang, Yaqin Wu, Haibo Shi, Shankai Yin, Yanmei Feng and Zhengnong Chen have nothing to disclose. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Compliance with Ethics Guidelines

The study protocol was approved and implemented according to the ethical standards of the Shanghai Jiaotong University Affiliated Sixth People’s Hospital ethics committee. Information of patients was anonymized and deidentified prior to analysis. The progress was conducted in accordance with the spirit of the Helsinki Declaration. All participants provided written informed consent for their inclusion in the database and the use of their data for research purposes.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Yanmei Feng or Zhengnong Chen.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zheng, Z., Shen, Y., Xia, L. et al. Glucocorticoid and Breviscapine Combination Therapy Versus Glucocorticoid Alone on Sudden Sensorineural Hearing Loss in Patients with Different Audiometric Curves. Adv Ther 37, 4959–4968 (2020). https://doi.org/10.1007/s12325-020-01513-9

Download citation

Keywords

  • Breviscapine
  • Glucocorticoid
  • Pure tone average
  • Vasodilator
  • Sudden sensorineural hearing loss